Investors should consider a strategic rotation out of overextended semiconductor stocks and into recovering enterprise software leaders like ServiceNow (NOW), MongoDB (MDB), and Workday (WDAY). Within the chip sector, Micron (MU) offers a compelling valuation at 10x to 13x forward earnings, though investors should trade the momentum cautiously due to potential long-term supply risks from China. In the high-growth memory space, Samsung (SSNLF) and SK Hynix (000660.KS) remain dominant plays as HBM4 supply shortages are expected to persist through the AI infrastructure build-out. For high-conviction biotech opportunities, Biohaven (BHVN) is highlighted as a top pick ahead of potential FDA approvals, while Abivax (ABVX) is positioned as a long-term winner despite recent market controversy. Avoid Capricor Therapeutics (CAPR) and Omeros (OMER), as sentiment remains bearish due to historical underperformance and fundamental concerns.

Micron Technology (MU)

• Micron is currently experiencing significant growth, with a 346% revenue growth year-over-year. • The company has $56 billion in property, plant, and equipment (PP&E) to generate approximately $28 billion in quarterly revenue. • High-Bandwidth Memory (HBM) currently accounts for about 15% of Micron's revenue, though this is a critical growth area for AI. • Management has highlighted the strategic value of memory in the AI era, noting multi-year strategic customer agreements that enhance financial predictability. • The company is investing at record levels in technology and supply to meet rapidly growing demand.

Takeaways

• Bullish Outlook: The memory cycle may be shifting from "cyclical" to "secular" (long-term growth) due to AI demand. • Valuation: The stock is trading at roughly 10x to 13x forward earnings, which is considered low if the current earnings "supra-cycle" is sustainable. • Risk Factors: The primary risk is a potential massive supply influx (particularly from Chinese competitors) that could eventually "cripple" pricing, as memory is still largely a commodity product compared to NVIDIA's proprietary chips. • Action: The analyst is currently trading the momentum but remains cautious about long-term sustainability, having sold some positions into the rally while keeping a decent-sized holding.

NVIDIA (NVDA)

• NVIDIA remains the "king of price increases" and controls the supply of GPUs. • There is a complex relationship between NVIDIA and memory suppliers (Micron, Hynix, Samsung); the analyst notes that NVIDIA's revenue was previously higher than the total HBM market, but that has recently inverted. • GPU Pricing: Mention of a "bearish report" from SemiAnalysis suggesting GPU pricing may be softening slightly.

Takeaways

• Market Power: NVIDIA is viewed as more valuable than the memory providers because it "controls supply," whereas memory is a standard product with various suppliers. • Sentiment: The analyst is starting to develop a "bearish reason" for NVIDIA but did not elaborate fully, noting that the "box" (GPU) should theoretically remain more valuable than the "commodity" (memory) inside it.

Samsung Electronics (SMSN / SSNLF)

• Samsung maintains a dominant 38.4% market share in the DRAM market. • The company is seeing stronger server product demand driven by AI infrastructure and "agentic AI." • Samsung is expanding its HBM4 supply to major customers and focusing on high-density DDR5.

Takeaways

• Supply Shortages: Samsung expects supply shortages to persist as they prioritize server-focused output over PC and mobile markets. • Growth: Like Micron, Samsung's memory revenue has seen explosive growth (roughly 4x), moving from ~$9-12 billion to ~$41-49 billion in comparable periods.

SK Hynix (000660.KS)

• Hynix is a major player in the HBM space with DRAM representing 76% of its business. • The analyst estimates that HBM revenue globally was approximately $20 billion last quarter, with Hynix being a primary beneficiary.

Takeaways

• HBM Dominance: Hynix is a "beast" in the sector, but the analyst questions if the market will ever give memory stocks the "multiple expansion" (higher valuation) they deserve compared to logic chip makers.

Biotech & Healthcare Mentions

• Abivax (ABVX): The analyst likes this stock "a lot" and believes it will have one of the "best-selling drugs," suggesting current controversies will be forgotten. • Sarepta Therapeutics (SRPT): Mentioned as a "buy," though the analyst is still building the position and noted it has been "struggling" recently. • Biohaven (BHVN): Noted as a "Back Up the Truck" recommendation that has performed well; potential FDA approval pending. • Capricor Therapeutics (CAPR): Bearish sentiment; referred to as "Stupid Capricor" for costing money in the past. The analyst plans to attend their upcoming Advisory Committee (AdCom) meeting. • Other mentions: BioCryst (BCRX) and Spruce Biosciences (SPRB) are being added to the analyst's portfolio. Omaros (OMER) received a negative opinion.

Takeaways

• Action: Focus on Abivax and Biohaven for potential upside, while remaining skeptical of Capricor.

Investment Themes: Software vs. Semiconductors

• Sector Rotation: The analyst observed a trend where "chips are down, software is up." • Software Recovery: Mentioned that "Software is back," noting rallies in ServiceNow (NOW), MongoDB (MDB), HubSpot (HUBS), and Workday (WDAY). • Robotics: Highlighted as the next major catalyst that will "eat a lot of this stuff" (chips and memory).

Takeaways

• Actionable Insight: Investors should look for a potential rotation out of overextended semiconductor stocks into recovering enterprise software stocks.